Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion dosed the first patient in a new arm of the OPAL study evaluating its investigational drug icovamenib in combination with low-dose semaglutide for obesity. The randomized, double-blind study aims to enroll 64 participants to assess whether adding icovamenib can enhance weight loss and improve physical function and body composition compared to semaglutide alone.
Key figures
- Drug Name
- icovamenib
- Phase Of Trial
- Phase 2
- Participants
- 64
- Icovamenib dose
- 100mg QD
- Primary endpoint week
- 24
- Dosing duration icovamenib
- 12 weeks
- Dosing duration semaglutide
- 24 weeks
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.